The principal effectiveness end point was incident infection with HIV type 1 or type 2 , as dependant on the presence of antibodies on two consecutive rapid tests conducted on plasma. Primary basic safety end points included quality 3 or more elevations in the alanine aspartate or aminotransferase aminotransferase level, grade 3 or more reductions in phosphorus, and grade 2 or higher elevations in the creatinine level; assessments were based on the grading desk of the Division of Helps and on local normal ranges.6 HIV-1 resistance was determined by using genotypic screening and phenotypic screening .Instead, they carried just the HLA haplotype shared by the donor and the recipient. On the other hand, blasts obtained at the proper time of medical diagnosis were heterozygous for the same loci. These findings show that genomic lack of the patient-specific HLA haplotype happened in vivo after transplantation. To determine the extent and the mechanism of the loss of heterozygosity in the individuals with relapsed leukemia, we performed microsatellite mapping and SNP arrays of chromosome 6, including the HLA region. In all five sufferers, the analyses showed loss of heterozygosity involving the brief arm of chromosome 6, encompassing the HLA region and causing lack of the patient-specific haplotype .